GoKawiilGenmab Shares Rise Following Positive Blood-Cancer Treatment Data
Genmab announced that its collaboration with AbbVie demonstrated that their drug Epkinly increased survival time for patients with a prevalent form of lymphoma. The results were presented in a recent study, prompting a surge in Genmab's stock price. The findings suggest potential for expanded use of the medication in blood cancer therapies.